We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App





A. Menarini and Credo Diagnostics Enter into Agreement for Distribution of SARS-CoV-2 Assay Kit

By LabMedica International staff writers
Posted on 03 Apr 2020
A. More...
Menarini Diagnostics (Florence, Italy) and Credo Diagnostics Biomedical (Singapore) have entered into an exclusive distribution agreement for the SARS-CoV-2 assay kit and other assays for the diagnosis of respiratory infections (RSV and group Strep A). The tests will be run on the VitaPCR (Credo Diagnostics Biomedical's Point-of-Care molecular testing platform) which allows the diagnosis of COVID-19 in just 20 minutes.

A. Menarini develops high tech diagnostics instruments and reagents to improve the quality of life of patients, providing healthcare professionals the best possible solutions to diagnostics needs. The company’s areas of expertise include self testing (self monitoring blood glucose, continuous glucose monitoring), clinical diagnostics (autoimmune testing, diabetes testing, hemoglobinopathies, urinalysis, urine sediment), infectious diseases (syndromic molecular testing) and tissue diagnostics (cellular pathology, forensics). Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of animal health, human health, and human wellness.

The COVID-19 molecular test and instrument are fundamental to both first aid facilities and intensive care units. These diagnostics kits adopt a reaction technology of the utmost accuracy on Point-of-Care instruments which are both compact (the size of a dictionary) and easy to use, giving a rapid diagnosis in settings such as emergency rooms, triage units, airports, seaports and railway stations. Once a nasal or oropharyngeal sample has been taken by a healthcare professional, this is inserted into a vial containing a liquid and shaken. The contents are then transferred into a second reagent tube which, once closed, will be placed inside the VitaPCR system, thus starting the analysis process. Within 20 minutes the test results are displayed on the instrument's built-in screen, confirming whether the sample analyzed has proven negative or positive.

"We have always believed that Point-of-Care molecular testing is the future. We look forward to working with Menarini to bring these tests to the market, especially in a crisis like this, to save lives," said Winston Wong Jr., Chairman of Credo Diagnostics Biomedical.

"Menarini Diagnostics has been working relentlessly over the past few weeks to find a way to help healthcare workers in the fight against the virus," said Fabio Piazzalunga, General Manager of Menarini Diagnostics. "We believe it is essential to have solutions which will allow the detection of positive cases, minimize times and take screening where it is needed, running tests both rapidly and with the most accurate technology possible. Thanks to this collaboration with Credo Diagnostics Biomedical, the Menarini Group hopes to be able to provide substantial support to healthcare workers."

Related Links:
A. Menarini Diagnostics
Credo Diagnostics Biomedical



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.